P-glycoprotein potentiates CYP3A4-mediated drug disappearance during Caco-2 intestinal secretory detoxification

Journal of Drug Targeting

Volumn 12, Issue 7, 2004, Pages 405-413

  Chan, Lauretta M S ^a   Cooper, Anne E ^b   Dudley, Adam L J ^b   Ford, Dianne ^a   Hirst, Barry H ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Absorption; Caco 2; CYP3A4; Intestine; P glycoprotein; Secretion

Indexed keywords

CALCITRIOL; CYTOCHROME P450 3A4; DIGOXIN; ERYTHROMYCIN; GLYCOPROTEIN P; TESTOSTERONE; VINBLASTINE;

ARTICLE; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DETOXIFICATION; DRUG TRANSPORT; ENZYME ACTIVITY; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; INTESTINE ABSORPTION; INTESTINE SECRETION; MONOLAYER CULTURE; PRIORITY JOURNAL; PROTEIN FUNCTION; STEROID HYDROXYLATION;

ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CACO-2 CELLS; CALCITRIOL; CYTOCHROME P-450 ENZYME SYSTEM; ERYTHROMYCIN; HUMANS; INTESTINES; METABOLIC DETOXICATION, DRUG; P-GLYCOPROTEIN; PHARMACEUTICAL PREPARATIONS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STIMULATION, CHEMICAL; TESTOSTERONE; VINBLASTINE;

EID: 9444272236     PISSN: 1061186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/10611860412331285224     Document Type: Article

References (39)

1. Barnes, K.M., Dickstein, B., Cutler, G.B., Fojo, T. and Bates, S.E. (1996) "Steroid transport, accumulation and antagonism of P-glycoprotein in multidrug-resistant cells", Biochemistry 35 4820-4827.
2. Benet, L.Z., Cummins, C.L. and Wu, C.Y. (2003) "Transporter-enzyme interactions: implications fro predicting drug-drug interactions from in vitro data", Curr. Drug Metab. 4, 393-398.
3. Cavet, M.E., West, M. and Simmons, N.L. (1996) "Transport and epithelial secretion of the cardiac glycoside, digoxin, by human intestinal epithelial (Caco-2) cells", Br. J. Pharmacol. 118 1389-1396.
4. Chan, L.M.S., Lowes, S. and Hirst, B.H. (2004) "The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability", Eur. J. Pharm. Sci. 21, 25-51.
5. Cummins, C.L., Jacobsen, W. and Benet, L.Z. (2002) "Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4", J. Pharmacol. Exp. Ther. 300, 1036-1045.
6. Cummins, C.L., Salphati, L., Reid, M.J. and Benet, L.Z. (2003) "In vivo modulation of CYP3A4 metabolism by P-glycoprotein: studies using the rat single-pass intestinal perfusion model", J. Pharmacol. Exp. Ther. 305, 306-314.
7. Engman, H.A., Lennernas, H., Taipalensuu, J., Otter, C., Leidvik, B. and Artursson, P. (2001) "CYP3A4, CYP3A5, and MDR1 in human small and large intestinal cell lines suitable for drug transport studies", J. Pharm. Sci. 90, 1736-1751.
8. Ever, R., Kool, M., Van Deemter, L., Janssen, H., Calafat, J., Oomen, L.C.J.M., Paulusma, C.C., Oude Elferink, R.P.J., Baas, F., Schinkel, A.H. and Borst, P. (1998) "Drug export activity of the human canalicular multispecific organic anion transporter in polarised kidney MDCK cells expressing cMOAT (MRP2) cDNX", J. Clin. Investig. 101, 1310-1319.
9. 3 modified Caco-2 cell monolayers" , J. Pharmacol. Exp. Ther. 289, 1134-1142.
10. Geick, A., Eichelbaum, M. and Burk, O. (2001) "Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin", J. Biol. Chem. 276, 14581-14587.
11. Hall, S.D., Thummel, K., Watkins, P.B., Lown, K.S., Benet, L.Z., Paine, M.F., Mayo, R.R., Turgeon, D.K., Bailey, D.G., Fontana, R.J. and Wrighton, S.A. (1999) "Molecular and physical mechanisms of first-pass extraction", Drug Metab. Dispos. 27, 161-166.
12. Hochman, J.H., Chiba, M., Nishime, J., Yamazaki, M. and Lin, J.H. (2000) "Influence of P-glycoprotein on the transport and metabolism of indinavir in Caco-2 cells expressing cytochrome P450 3A4", J. Pharmacol. Exp. Ther. 292, 310-318.
13. Hu, M., Li, Y., Davitt, C.M., Huang, S.M., Thummel, K., Penman, B.W. and Crespi, C.L. (1999) "Transport and metabolic characterisation of Caco-2 cells expressing CYP3A4 and CYP3A4 plus oxidoreductase", Pharm. Res. 16, 1352-1359.
14. Hunter, J. and Hirst, B.H. (1997) "Intestinal secretion of drugs. The role of P-glycoprotein and related drug efflux systems in limiting oral drug absorption", Adv. Drug Deliv. Rev. 25, 129-157.
15. Hunter, J., Hirst, B.H. and Simmons, N.L. (1991) "Transepithelial vinblastine secretion mediated by P-glycoprotein is inhibited by forskolin derivatives", Biochem. Biophys. Res. Commun. 181, 671-676.
16. Hunter, J., Jepson, M., Tsuruo, T., Simmons, N.L. and Hirst, B.H. (1993a) "Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells. Kinetics of vinblastine secretion and interaction with modulators", J. Biol. Chem. 268 14991-14997.
17. Hunter, J., Hirst, B.H. and Simmons, N.L. (1993b) "Drug absorption limited by P-glycoprotein-mediated secretory drug transport in human intestinal epithelial Caco-2 cell layers", Pharm. Res. 10 743-749.
18. Ito, K., Kusuhara, H. and Sugiyama, Y. (1999) "Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption-theoretical approach", Pharm. Res. 16, 225-231.
19. Juliano, R.L. and Ling, V. (1976) "A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants", Biochem. Biaphys. Acta 455, 152-162.
20. Lacarelle, K.B., Rahmani, R., De Sousa, G., Placidi, M. and Cano, J.P. (1991) "Metabolism of digoxin, digoxigenin digitoxosides and digoxigenin in human hepatocytes and liver microsomes", Fundam. Clin. Pharmacol. 5, 567-582.
21. Lan, L.B., Dalton, J.T. and Schuetz, E.G. (2000) "Mdr1 limits CYP3A metabolism in vivo", Mol. Pharmacol. 58, 863-869.
22. Lentz, K.A., Polli, J.W., Wring, S.A., Humphreys, J.E. and Polli, J.E. (2000) "Influence of passive permeability on apparent P-glycoprotein kinetics", Pharm. Res. 17, 1456-1460.
23. Ling, V. and Thompson, L.H. (1974) "Reduced permeability in CHO cells as a mechanism of resistance to colchicine", J. Cell. Physiol. 83, 103-116.
24. Lowes, S., Cavet, M.E. and Simmons, N.L. (2003) "Evidence for a non-MDR1 component in digoxin secretion by human intestinal Caco-2 epithelial cells", Eur. J. Pharmacol. 458, 49-56.
25. Prime-Chapman, H.M., Rearn, R.A., Cooper, A.E., Moore, V. and Hirst, B.H. (2004) "Differential multidrug resistance-associated protein 1 through 6 isoform expression and function in human intestinal epithelial Caco-2 cells", J. Pharmacol. Exp. Ther., 2004 Jun 21; jpct 104.068775 [Epub ahead of print].
26. Qian, X.D. and Beck, W.T. (1990) "Progesterone photoaffinity labels P-glycoprotein in multidrug-resistant human leukemic lymphoblasts", J. Biol. Chem. 265, 18753-18756.
27. 3", Mol. Pharmacol. 51, 741-754.
28. Schuetz, E.G., Beck, W.T. and Schuetz, J.D. (1996) "Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells", Mol. Pharmacol. 49, 311-318.
29. Suzuki, H. and Sugiyama, Y. (2000) "Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine", Eur. J. Pharm. Sci. 12, 3-12.
30. Synold, T.W., Dussault, I. and Forman, B.M. (2001) "The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux", Nat. Med. 7, 584-590.
31. Taipalensuu, J., Tornblom, H., Lindberg, G., Einarsson, C., Sjoqvist, F., Melhus, H., Garberg, P., Sjostrom, B., Lundgren, B. and Artursson, P. (2001) "Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers", J. Pharmacol. Exp. Ther. 299, 164-170.
32. Takano, M., Hasegawa, R., Fukuda, T., Yumoto, R., Nagai, J. and Murakami, T. (1998) "Interaction with P-glycoprotein and transport of erythromycin, midazolam, and ketoconazole in Caco-2 cells", Eur. J. Pharmacol. 358, 289-294.
33. Thiebaut, F., Tsuruo, T., Hamada, H., Gottesman, M.M., Pastan, I. and Willingham, M.C. (1987) "Cellular localisation of the multidrug-resistance gene product P-glycoprotein in normal human tissues", Proc. Natl Acad. Sci. USA 84, 7735-7738.
34. Wacher, V.J., Wu, C.Y. and Benet, L.Z. (1995) "Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy", Mol. Carcinogen. 13, 129-134.
35. Wang, R.W., Newton, D.J., Scheri, T.D. and Lu, A.Y.H. (1997) "Human cytochrome P450 3A4-catalysed testosterone 6β -hydroxylation and erythromycin N-demethylation", Drug Metab. Dispos. 25, 502-507.
36. Watkins, P.B. (1997) "The barrier function of CYP3A4 and P-glycoprotein in the small bowel", Adv. Drug Deliv. Rev. 27 161-170.
37. Waxman, D.J., Attisano, C., Guengerich, F.P. and Lapenson, D.P. (1988) "Human liver microsomal steroid metabolism: identification of the major microsomal steroid hormone 6β -hydroxylase cytochrome P450 enzyme", Arch. Biochem. Biophys. 263, 424-436.
38. Yamazaki, H. and Shimada, T. (1997) "Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9 and 3A4 in human liver microsomes", Arch. Biochem. Biophys. 346, 161-169.
39. Zhou, P.X., Seree, E., Zhou, X.J., Placidi, M., Maurel, P., Barra, Y. and Rashmani, R. (1993) "Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions", Cancer Res. 53, 5121-5126.